<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28162159</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[The value of different antibodies detection in diagnosis of rheumatism with uveitis].</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>290</EndPage><MedlinePgn>285-290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0376-2491.2017.04.010</ELocationID><Abstract><AbstractText><b>Objective:</b> To investigate the value of HLA-B27 antigen, antinuclear antibody (ANA), anti-dsDNA and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) detection in diagnosis of rheumatism with uveitis. <b>Methods:</b> Seven hundred and twenty four newly diagnosed patients with non-infection uveitis in Beijing Tongren Hospital from March 2012 to March 2016 who long-term lived in Beijing and its surrounding areas were continuously enrolled. HLA-B27 antigen expressions in peripheral blood lymphocytes and ANA, anti-dsDNA and ANCA levels in serum were tested. The detailed clinical data, imaging examinations and pathological examinations were recorded to define whether the patients had rheumatism and the types of rheumatism. <b>Results:</b> There were 285 patients were diagnosed with rheumatism in 724 patients (39.4%), with 135 male (47.4%) and 150 female (52.6%). The mean age of male (41&#xb1;14) was lower than that of female (44&#xb1;14), with statistically significant (<i>t</i>=2.18, <i>P</i>&lt;0.05). There were 176 patients with Spondyloarthropathies, 48 patients with primary systemic vasculitis, 22 patients with systemic lupus erythematosus, 18 patients with primary Sjogren's syndrome, 16 patients with rheumatoid arthritis and 5 patients with juvenile idiopathic arthritis in 285 rheumatism patients. The positive rate of HLA-B27(57.2%), ANA(15.8%), anti-dsDNA (5.3%) and ANCA(9.1%) in rheumatic uveitis patients were obviously higher than those of non-rheumatic uveitis patients [HLA-B27(1.1%), ANA(1.6%), anti-dsDNA (0.0%) and ANCA(0.9%)], with statistically significant (<i>Fisher</i>'<i>s exact test, P</i>&lt;0.01). The HLA-B27 positive antigen were mainly in patients with Spondyloarthropathies, rate was 92.1%; the positive ANA were mainly in patients with systemic lupus erythematosus, rate was 95.5%; the positive anti-dsDNA were mainly in patients with systemic lupus erythematosus, rate was 59.1%; the positive ANCA were mainly in patients with primary systemic vasculitis (besides Behcet disease), rate was 57.1%. <b>Conclusions:</b> The detections of HLA-B27 antigen, ANA, anti-dsDNA and ANCA are valuable for primary screening of some rheumatic uveitis. There fore, clinicians should select targeted laboratory examination combine with the patients' clinical manifestations. This will be helpful in the auxiliary diagnosis of some types of rheumatic uveitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>X F</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y H</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>X X</ForeName><Initials>XX</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015796">HLA-B27 Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001171" MajorTopicYN="N">Arthritis, Juvenile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001528" MajorTopicYN="N">Behcet Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015796" MajorTopicYN="N">HLA-B27 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025242" MajorTopicYN="N">Spondylarthropathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014605" MajorTopicYN="Y">Uveitis</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x63a2;&#x8ba8;&#x4eba;&#x7c7b;&#x767d;&#x7ec6;&#x80de;B27&#x6297;&#x539f;(HLA&#xff0d;B27)&#x3001;&#x6297;&#x6838;&#x6297;&#x4f53;(ANA)&#x3001;&#x6297;&#x53cc;&#x94fe;DNA&#x6297;&#x4f53;(anti&#xff0d;dsDNA)&#x548c;&#x6297;&#x4e2d;&#x6027;&#x7c92;&#x7ec6;&#x80de;&#x80de;&#x8d28;&#x6297;&#x4f53;(ANCA)&#x68c0;&#x6d4b;&#x5bf9;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x7684;&#x8bca;&#x65ad;&#x4ef7;&#x503c;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x8fde;&#x7eed;&#x6536;&#x96c6;2012&#x5e74;3&#x6708;&#x81f3;2016&#x5e74;3&#x6708;&#x5c31;&#x8bca;&#x4e8e;&#x5317;&#x4eac;&#x540c;&#x4ec1;&#x533b;&#x9662;&#x4e14;&#x957f;&#x671f;&#x751f;&#x6d3b;&#x4e8e;&#x5317;&#x4eac;&#x53ca;&#x5176;&#x5468;&#x8fb9;&#x5730;&#x533a;&#x7684;&#x521d;&#x8bca;&#x975e;&#x611f;&#x67d3;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;724&#x4f8b;&#xff0c;&#x68c0;&#x6d4b;&#x60a3;&#x8005;&#x5916;&#x5468;&#x8840;&#x6dcb;&#x5df4;&#x7ec6;&#x80de;HLA&#xff0d;B27&#x6297;&#x539f;&#x8868;&#x8fbe;&#x548c;&#x8840;&#x6e05;&#x4e2d;ANA&#x3001;anti&#xff0d;dsDNA&#x548c;ANCA&#x8868;&#x8fbe;&#x60c5;&#x51b5;&#xff0c;&#x5e76;&#x901a;&#x8fc7;&#x6536;&#x96c6;&#x8be6;&#x7ec6;&#x4e34;&#x5e8a;&#x8d44;&#x6599;&#xff0c;&#x7ed3;&#x5408;&#x5f71;&#x50cf;&#x5b66;&#x548c;&#x75c5;&#x7406;&#x5b66;&#x68c0;&#x67e5;&#x7b49;&#x660e;&#x786e;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;&#x662f;&#x5426;&#x60a3;&#x6709;&#x98ce;&#x6e7f;&#x75c5;&#x53ca;&#x98ce;&#x6e7f;&#x75c5;&#x7c7b;&#x578b;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> 724&#x4f8b;&#x521d;&#x53d1;&#x975e;&#x611f;&#x67d3;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x5171;&#x786e;&#x8bca;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;285&#x4f8b;(&#x5360;39.4%)&#xff1b;&#x5176;&#x4e2d;&#x7537;135&#x4f8b;&#xff0c;&#x5360;47.4%&#xff0c;&#x5973;150&#x4f8b;&#xff0c;&#x5360;52.6%&#xff1b;&#x7537;&#x6027;&#x60a3;&#x8005;&#x7684;&#x5e73;&#x5747;&#x5e74;&#x9f84;&#x4e3a;(41&#xb1;14)&#x5c81;&#xff0c;&#x4f4e;&#x4e8e;&#x5973;&#x6027;&#x60a3;&#x8005;&#x7684;&#x5e73;&#x5747;&#x5e74;&#x9f84;(44&#xb1;14)&#x5c81;&#xff0c;&#x5dee;&#x5f02;&#x6709;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;(<i>t</i>&#xff1d;2.18&#xff0c;<i>P</i>&lt;0.05)&#x3002;285&#x4f8b;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x5305;&#x62ec;176&#x4f8b;&#x810a;&#x67f1;&#x5173;&#x8282;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3001;48&#x4f8b;&#x539f;&#x53d1;&#x6027;&#x7cfb;&#x7edf;&#x6027;&#x8840;&#x7ba1;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3001;22&#x4f8b;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3001;18&#x4f8b;&#x539f;&#x53d1;&#x6027;&#x5e72;&#x71e5;&#x7efc;&#x5408;&#x5f81;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3001;16&#x4f8b;&#x7c7b;&#x98ce;&#x6e7f;&#x6027;&#x5173;&#x8282;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3001;5&#x4f8b;&#x5e7c;&#x5e74;&#x6027;&#x7279;&#x53d1;&#x6027;&#x5173;&#x8282;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x3002;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;HLA&#xff0d;B27(57.2%)&#x3001;ANA(15.8%)&#x3001;anti&#xff0d;dsDNA(5.3%)&#x548c;ANCA(9.1%)&#x7684;&#x9633;&#x6027;&#x7387;&#x660e;&#x663e;&#x9ad8;&#x4e8e;&#x975e;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;HLA&#xff0d;B27(1.1%)&#x3001;ANA(1.6%)&#x3001;anti&#xff0d;dsDNA(0)&#x548c;ANCA(0.9%)&#x7684;&#x9633;&#x6027;&#x7387;&#xff0c;&#x5dee;&#x5f02;&#x5747;&#x6709;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;(<i>Fisher</i>&#x7cbe;&#x786e;&#x6982;&#x7387;&#x68c0;&#x9a8c;&#xff0c;<i>P</i>&#x5747;&lt;0.01)&#xff1b;HLA&#xff0d;B27&#x6297;&#x539f;&#x9633;&#x6027;&#x4e3b;&#x8981;&#x8868;&#x73b0;&#x5728;&#x810a;&#x67f1;&#x5173;&#x8282;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;&#xff0c;&#x9633;&#x6027;&#x7387;&#x4e3a;92.1%&#xff1b;ANA&#x9633;&#x6027;&#x4e3b;&#x8981;&#x8868;&#x73b0;&#x5728;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;&#xff0c;&#x9633;&#x6027;&#x7387;&#x4e3a;95.5%&#xff1b;anti&#xff0d;dsDNA&#x9633;&#x6027;&#x4e3b;&#x8981;&#x8868;&#x73b0;&#x5728;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;&#xff0c;&#x9633;&#x6027;&#x7387;&#x4e3a;59.1%&#xff1b;ANCA&#x9633;&#x6027;&#x4e3b;&#x8981;&#x8868;&#x73b0;&#x5728;&#x539f;&#x53d1;&#x6027;&#x7cfb;&#x7edf;&#x6027;&#x8840;&#x7ba1;&#x708e;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x60a3;&#x8005;(&#x9664;&#x5916;&#x767d;&#x585e;&#x75c5;)&#xff0c;&#x9633;&#x6027;&#x7387;&#x4e3a;57.1%&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> HLA&#xff0d;B27&#x6297;&#x539f;&#x3001;ANA&#x3001;anti&#xff0d;dsDNA&#x548c;ANCA&#x68c0;&#x6d4b;&#x5bf9;&#x90e8;&#x5206;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x7684;&#x8bca;&#x65ad;&#x6709;&#x8f83;&#x597d;&#x7684;&#x521d;&#x7b5b;&#x4f5c;&#x7528;&#xff0c;&#x4e34;&#x5e8a;&#x533b;&#x751f;&#x5e94;&#x7ed3;&#x5408;&#x60a3;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#xff0c;&#x9009;&#x62e9;&#x6709;&#x9488;&#x5bf9;&#x6027;&#x7684;&#x5b9e;&#x9a8c;&#x5ba4;&#x68c0;&#x67e5;&#xff0c;&#x6709;&#x52a9;&#x4e8e;&#x90e8;&#x5206;&#x98ce;&#x6e7f;&#x75c5;&#x6027;&#x8461;&#x8404;&#x819c;&#x708e;&#x7c7b;&#x578b;&#x7684;&#x8f85;&#x52a9;&#x8bca;&#x65ad;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Antigens</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Uveitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28162159</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.0376-2491.2017.04.010</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>